Ronald M. Du Bois
#147,495
Most Influential Person Now
Ronald M. Du Bois's AcademicInfluence.com Rankings
Ronald M. Du Boisphilosophy Degrees
Philosophy
#7999
World Rank
#11297
Historical Rank
Logic
#5033
World Rank
#6390
Historical Rank
Download Badge
Philosophy
Ronald M. Du Bois's Degrees
- PhD Biomedical Sciences University of California, San Francisco
- Doctorate Medicine Stanford University
Why Is Ronald M. Du Bois Influential?
(Suggest an Edit or Addition)Ronald M. Du Bois's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. (2014) (1576)
- ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. (1999) (1227)
- Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. (2011) (922)
- Interstitial lung disease in systemic sclerosis: a simple staging system. (2008) (905)
- A common MUC5B promoter polymorphism and pulmonary fibrosis. (2011) (880)
- Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. (2005) (815)
- An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. (2012) (746)
- Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. (2002) (744)
- An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features (2015) (704)
- A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. (2006) (663)
- BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. (2011) (617)
- Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis (2013) (606)
- Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. (2006) (598)
- Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. (2003) (590)
- Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. (2003) (572)
- Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. (2008) (485)
- The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. (2000) (483)
- Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. (2011) (391)
- Quantitative Analysis of Mycobacterial and Propionibacterial DNA in Lymph Nodes of Japanese and European Patients with Sarcoidosis (2002) (387)
- Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. (2011) (383)
- Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. (2004) (378)
- Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. (2004) (369)
- A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. (1999) (366)
- Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. (2010) (366)
- Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. (2008) (340)
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials (2016) (333)
- Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. (2016) (332)
- CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. (2004) (329)
- Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease (2013) (305)
- Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis (2004) (304)
- Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis (2009) (304)
- BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. (2008) (301)
- Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. (2001) (294)
- The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. (2002) (290)
- Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. (2011) (278)
- Connective tissue disease-associated interstitial lung disease: a call for clarification. (2010) (272)
- 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. (1998) (260)
- Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. (1994) (257)
- Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF (2004) (247)
- Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. (1997) (244)
- Structural features of interstitial lung disease in systemic sclerosis. (1991) (239)
- Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? (2007) (227)
- Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. (1997) (224)
- The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. (1993) (215)
- Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. (2000) (213)
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease (2006) (213)
- Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. (2004) (211)
- Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease (1999) (209)
- Acute interstitial pneumonia. (2000) (206)
- Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. (1993) (203)
- The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. (2010) (200)
- High resolution computed tomography as a predictor of lung histology in systemic sclerosis. (1992) (199)
- Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. (2000) (193)
- Interstitial vascularity in fibrosing alveolitis. (2003) (185)
- Expression of the neutrophil elastase gene during human bone marrow cell differentiation (1989) (185)
- Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume (2016) (184)
- Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. (2012) (180)
- Endothelin-1 Induces Expression of Matrix-associated Genes in Lung Fibroblasts through MEK/ERK* (2004) (176)
- 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis (2013) (172)
- HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. (2002) (170)
- Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts. (2007) (169)
- Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. (1997) (167)
- Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. (2007) (164)
- A polymorphism in the CTGF promoter region associated with systemic sclerosis. (2007) (159)
- Idiopathic pulmonary fibrosis: outcome in relation to smoking status. (2008) (156)
- Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors (2006) (153)
- Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. (1997) (150)
- Acute exacerbation of interstitial pneumonia following surgical lung biopsy. (2006) (150)
- Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis (2016) (147)
- Natural history of hepatic sarcoidosis and its response to treatment (2006) (142)
- BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia (2003) (141)
- The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference (2009) (138)
- Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking (2004) (136)
- Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts (2004) (136)
- Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. (2002) (135)
- Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. (1994) (135)
- Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. (1997) (135)
- Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. (2009) (134)
- Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. (2000) (133)
- Influence of MHC CLASS II in Susceptibility to Beryllium Sensitization and Chronic Beryllium Disease 1 (2003) (131)
- Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. (2011) (129)
- Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. (2002) (129)
- Terminal diffuse alveolar damage in relation to interstitial pneumonias. An autopsy study. (2003) (126)
- Is there a role for microorganisms in the pathogenesis of sarcoidosis? (2003) (123)
- All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. (2014) (122)
- Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT features. (2003) (119)
- CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. (2000) (118)
- Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. (2010) (117)
- Bronchoalveolar lavage cellularity: lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis. (1998) (116)
- HLA-DP Allele-Specific T Cell Responses to Beryllium Account for DP-Associated Susceptibility to Chronic Beryllium Disease1 (2001) (115)
- Observer variation in pattern type and extent of disease in fibrosing alveolitis on thin section computed tomography and chest radiography. (1994) (113)
- Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance. (1994) (112)
- Localisation of transforming growth factor β1 and β3 mRNA transcripts in normal and fibrotic human lung (2001) (111)
- Familial sarcoidosis is linked to the major histocompatibility complex region. (2000) (110)
- Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. (2007) (108)
- Exhaled nitric oxide is increased in active fibrosing alveolitis. (1999) (107)
- Genetic variation and response to morphine in cancer patients (2008) (106)
- Epidemiology of familial sarcoidosis in the UK. (2000) (105)
- Genetics of fibrosing lung diseases (2005) (105)
- Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. (2001) (104)
- C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. (2003) (104)
- Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials (2016) (100)
- No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. (2006) (100)
- Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. (1999) (99)
- Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (2014) (97)
- HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. (1998) (97)
- Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis (2017) (96)
- Diverse cellular TGF-beta 1 and TGF-beta 3 gene expression in normal human and murine lung. (1996) (93)
- Accuracy of the typical computed tomographic appearances of fibrosing alveolitis. (1993) (93)
- Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. (2009) (93)
- The role of small airways in lung disease. (2002) (92)
- Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. (1993) (92)
- Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. (2009) (90)
- Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. (2011) (89)
- Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. (1999) (85)
- Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. (2012) (84)
- Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. (1997) (83)
- T-lymphocytes that accumulate in the lung in sarcoidosis have evidence of recent stimulation of the T-cell antigen receptor. (1992) (83)
- Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. (2001) (82)
- Human neutrophils express the alpha 1-antitrypsin gene and produce alpha 1-antitrypsin. (1991) (82)
- Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. (2003) (79)
- Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. (1985) (79)
- Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. (2007) (78)
- Sarcoidosis: genes and microbes--soil or seed? (2001) (77)
- Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. (2015) (76)
- Lymphocyte activation and destruction in vitro in relation to MLC and HL-A. (1973) (75)
- Alveolar proteinosis: diagnosis and treatment over a 10-year period. (1983) (74)
- Bronchiolitis in association with connective tissue disorders. (1993) (74)
- L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. (1993) (73)
- CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis (2009) (73)
- Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. (2016) (73)
- Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis (2015) (73)
- Visual loss in sarcoid‐related uveitis (2003) (72)
- The value of classifying interstitial pneumonitis in childhood according to defined histological patterns (1998) (70)
- Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. (2001) (69)
- Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. (2012) (67)
- Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. (1991) (67)
- The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. (2004) (67)
- Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium. (1995) (66)
- Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans. (1997) (66)
- Challenges in pulmonary fibrosis · 5: The NSIP/UIP debate (2007) (66)
- C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. (2005) (66)
- Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia (2016) (66)
- Genetic determinants of pulmonary fibrosis: evolving concepts. (2014) (64)
- Insulin-like growth factor-I is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. (1994) (64)
- Interleukin 1alpha single-nucleotide polymorphism associated with systemic sclerosis. (2004) (63)
- Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. (1997) (63)
- Primary epithelioid angiosarcoma of the lung presenting as pulmonary hemorrhage. (1997) (63)
- Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. (1999) (62)
- Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis (2009) (62)
- The source and role of RANTES in interstitial lung disease. (1997) (62)
- Activated neutrophils secrete stored alpha 1-antitrypsin. (1996) (61)
- Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. (2010) (61)
- Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. (1999) (59)
- A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer (2012) (59)
- PSMB2 and RPL32 are suitable denominators to normalize gene expression profiles in bronchoalveolar cells (2008) (58)
- Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. (2008) (57)
- Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. (1997) (56)
- Rheumatoid arthritis and cryptogenic organising pneumonitis. (1991) (56)
- Analysis of MHC encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis. (1999) (55)
- Functional impairment in fibrosing alveolitis: relationship to reversible disease on thin section computed tomography. (1997) (55)
- Immunocompetent cells in bronchoalveolar lavage reflect the cell populations in transbronchial biopsies in pulmonary sarcoidosis. (2015) (53)
- Role of bronchoalveolar lavage in the evaluation of interstitial pneumonitis in recipients of bone marrow transplants. (1987) (52)
- A common haplotype of the C‐C chemokine receptor 2 gene and HLA‐DRB1*0301 are independent genetic risk factors for Löfgren’s syndrome (2008) (52)
- TNF-857T, a genetic risk marker for acute anterior uveitis. (2005) (52)
- Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. (2007) (51)
- Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. (1997) (51)
- CC and C chemokine expression in pulmonary sarcoidosis (2002) (49)
- Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) (2009) (48)
- Relation between immunocytological features of bronchoalveolar lavage fluid and clinical indices in sarcoidosis. (1989) (48)
- Protein profiles of bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. (2006) (48)
- Endothelin axis polymorphisms in patients with scleroderma. (2006) (47)
- Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. (2003) (47)
- Analysis of IL-12 p40 subunit gene and IFN-γ G5644A polymorphisms in Idiopathic Pulmonary Fibrosis (2003) (46)
- Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. (2001) (46)
- Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Patients with Chronic Pulmonary Sarcoidosis (2011) (46)
- Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. (2001) (46)
- Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Löfgren's syndrome in Czech patients with sarcoidosis. (2005) (45)
- Rare lung disease and orphan drug development. (2013) (43)
- Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis (2012) (43)
- Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. (2004) (42)
- Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. (2001) (42)
- Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. (1999) (41)
- Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease. (1986) (41)
- TGF-β1 Variants in Chronic Beryllium Disease and Sarcoidosis1 (2007) (41)
- The density of HLA-DR antigen expression on alveolar macrophages is increased in pulmonary sarcoidosis. (1986) (40)
- The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. (1997) (40)
- The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. (2002) (40)
- Increased Vitronectin and Endothelin-1 in the Breath Condensate of Patients with Fibrosing Lung Disease (2003) (39)
- Increased epithelial permeability in pulmonary fibrosis in relation to disease progression (2010) (38)
- Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. (2009) (38)
- Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. (1996) (37)
- Up‐regulation of IL‐8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis (1997) (37)
- An earlier and more confident diagnosis of idiopathic pulmonary fibrosis (2012) (37)
- Variation in iron homeostasis genes between patients with ARDS and healthy control subjects. (2008) (37)
- Optimal scoring of serial change on chest radiography in sarcoidosis. (2011) (36)
- Abnormal ventricular long-axis function in systemic sclerosis. (1995) (36)
- Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program (2011) (35)
- Comprehensive HLA-DP typing using polymerase chain reaction with sequence-specific primers and 95 sequence-specific primer mixes. (1998) (35)
- Expression of the chemokine PARC mRNA in bronchoalveolar cells of patients with sarcoidosis. (2002) (34)
- Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis (2009) (34)
- Rapid genotyping of transforming growth factor beta1 gene polymorphisms in a UK Caucasoid control population using the polymerase chain reaction and sequence-specific primers. (1998) (34)
- Immunological mechanisms in sarcoidosis (2001) (34)
- Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs. (1982) (34)
- Analysis of IL6 and IL1A gene polymorphisms in UK and Dutch patients with sarcoidosis. (2003) (33)
- Idiopathic pulmonary haemosiderosis: a form of microscopic polyarteritis? (1992) (32)
- Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. (2003) (32)
- TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. (2007) (32)
- Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. (2007) (31)
- Polymorphic analysis of the high-affinity tumor necrosis factor receptor 2. (1999) (30)
- The importance of sarcoidosis genotype to lung phenotype. (2003) (29)
- Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. (2005) (29)
- T-helper cell type-1 transcription factor T-bet is upregulated in pulmonary sarcoidosis (2011) (29)
- CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. (2002) (29)
- Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. (1998) (29)
- Mapping of the immunodominant T cell epitopes of the protein topoisomerase I (2004) (29)
- Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis (2009) (28)
- Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data. (2014) (28)
- Challenges in pulmonary fibrosis: 8 · The need for an international registry for idiopathic pulmonary fibrosis (2008) (27)
- Ocular Features in Neurosarcoidosis (2009) (26)
- Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. (2009) (26)
- Mechanisms of scleroderma-induced lung disease. (2007) (25)
- The distribution of phenotypically distinct macrophage subsets in the lungs of patients with cryptogenic fibrosing alveolitis. (1989) (25)
- No association between interleukin-18 gene polymorphisms and haplotypes in Dutch sarcoidosis patients. (2004) (25)
- Strategies for treating idiopathic pulmonary fibrosis. (2010) (25)
- Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis (2013) (25)
- Analysis of KL-6 and SP-D as disease markers in bird fancier's lung. (2005) (25)
- Prediction of disease progression in idiopathic pulmonary fibrosis. (1994) (24)
- The complex interrelationships between chronic lung and liver disease: a review (2010) (24)
- Surfactant gene polymorphisms and interstitial lung diseases (2001) (23)
- TNF polymorphism and bronchoalveolar lavage cell TNF-alpha levels in chronic beryllium disease and beryllium sensitization. (2007) (22)
- Advanced multiple beam equalization radiography (AMBER) in the detection of diffuse lung disease. (1991) (22)
- Brief Report: Anti–Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis (2016) (22)
- Expression analysis of extracellular microRNA in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis (2018) (22)
- Recent advances in the diagnosis and management of nonspecific interstitial pneumonia (2003) (22)
- Respiratory bronchiolitis-associated interstitial lung disease. (2003) (21)
- Association of Toll-like receptor 4 alleles with symptoms and sensitization to laboratory animals. (2008) (21)
- BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals. (2007) (20)
- Diffuse lung disease: product of genetic susceptibility and environmental encounters. (1997) (20)
- Suppression associated lymphocyte markers in lesions of sarcoidosis. (1988) (20)
- Density gradient of the lung parenchyma at computed tomographic scanning in patients with pulmonary hypertension and systemic sclerosis. (1996) (20)
- A single round PCR method for genotyping human surfactant protein (SP)-A1, SP-A2 and SP-D gene alleles. (2003) (20)
- Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. (2008) (18)
- Obliterative bronchiolitis, cryptogenic organising pneumonitis and bronchiolitis obliterans organizing pneumonia: three names for two different conditions. (1991) (18)
- Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. (1999) (18)
- Oligoclonal V gene usage by T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients. (1996) (18)
- Tumour necrosis factor-α production in fibrosing alveolitis is macrophage subset specific (2001) (18)
- PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. (2008) (17)
- A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis (2006) (17)
- Intracellular cytokine profiles and T cell activation in pulmonary sarcoidosis. (2008) (17)
- Hypoxemia and Arrhythmia during Daily Activities and Six-minute Walk Test in Fibrotic Interstitial Lung Diseases (2011) (16)
- Lung biopsy in diffuse parenchymal lung disease. (2001) (16)
- Adhesion molecule expression in the lung: a comparison between normal and diffuse interstitial lung disease. (1998) (15)
- Can lung function measurements be used to predict which patients will be at risk of developing interstitial pneumonitis after bone marrow transplantation? (1992) (15)
- CC chemokine receptor 5 gene polymorphisms in beryllium disease (2010) (15)
- The genetic predisposition to interstitial lung disease: functional relevance. (2002) (15)
- HLA‐DQB1*0602 allele is associated with splenomegaly in Japanese sarcoidosis (2007) (15)
- Genetic factors in pulmonary fibrotic disorders. (2006) (14)
- Diffuse lung disease: a view for the future. (1997) (14)
- Pulmonary cell populations in recipients of bone marrow transplants with interstitial pneumonitis. (1989) (14)
- Peripheral-type benzodiazepine receptors in bronchoalveolar lavage cells of patients with interstitial lung disease. (2007) (14)
- Idiopathic pulmonary fibrosis trials: recommendations for the jury (2011) (13)
- Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. (2003) (13)
- Complement receptor 1 single nucleotide polymorphisms in Czech and Dutch patients with sarcoidosis. (2007) (13)
- Pulmonary capillaritis and its relationship to development of emphysema in hypocomplementaemic urticarial vasculitis syndrome. (2006) (13)
- The Clara cell10 adenine38guanine polymorphism and sarcoidosis susceptibility in Dutch and Japanese subjects. (2004) (12)
- HLA-DPB1 and TAP1 polymorphisms in sarcoidosis. (1997) (12)
- The CR1 C5507G polymorphism is not involved in susceptibility to idiopathic pulmonary fibrosis in two European populations. (2008) (11)
- The MCP-1-2518 (A to G) single nucleotide polymorphism in Czech patients with pulmonary sarcoidosis: association with Löfgren's syndrome. (2007) (11)
- Congenital and pediatric interstitial disease (1996) (11)
- The effect of lung biopsy on lung function in diffuse lung disease. (2000) (11)
- Lymphocyte activation and destruction in vitro in relation to MLC and HL-A. (1973) (11)
- Cells, Enzymes and Interstitial Lung Disease (1981) (11)
- Idiopathic pulmonary fibrosis. (1993) (11)
- Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis. (2006) (10)
- Autoantibodies in cryptogenic fibrosing alveolitis (2001) (10)
- T‐cell receptor gene usage in patients with fibrosing alveolitis and control subjects (1999) (10)
- The pulmonary physician in critical care • Illustrative case 2: Interstitial lung disease (2003) (9)
- Alveolar macrophage lysosomal enzyme and C3b receptors in cryptogenic fibrosing alveolitis. (1980) (9)
- Bronchiolitis obliterans, cryptogenic organising pneumonitis and BOOP. (1991) (9)
- Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans. (2008) (8)
- Humoral immune responses within the lung of bone marrow transplant recipients studied by bronchoalveolar lavage. (1988) (8)
- Rare lung diseases: orphans no more? (2002) (7)
- Activation of peripheral blood mononuclear cells in bronchoalveolar lavage fluid from patients with sarcoidosis: visualisation of single cell activation products. (1994) (7)
- Recent advances in the immunology of interstitial lung disease. (1991) (6)
- Is idiopathic pulmonary fibrosis now treatable? (2005) (6)
- Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? (2011) (6)
- Single-cell analysis: a novel approach to tumour necrosis factor-α synthesis and secretion in sarcoidosis (2002) (6)
- Diffuse lung disease: an approach to management. (1994) (6)
- Matrix metalloproteinase-7 expression in fibrosing lung disease: restoring the balance. (2008) (5)
- Idiopathic pulmonary fibrosis: present understanding and future options (2011) (5)
- Interstitial lung disease: basic mechanisms and genetic predisposition. (1997) (5)
- Chemotactic cytokines (chemokines) and their role in physiological and immunopathological reactions. (1995) (5)
- Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis (2008) (5)
- Non-invasive ventilation in hypercapnic respiratory failure secondary to sclerodermic chest wall restriction. (1998) (5)
- Chymase Gene (CMA1) Polymorphisms in Dutch and Japanese Sarcoidosis Patients (2006) (4)
- 6-minute walk distance as a predictor of outcome in idiopathic pulmonary fibrosis (2014) (4)
- Skin testing in hospital. (1977) (4)
- Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. (1999) (3)
- Rheumatoid factor in a patient with Reiter's disease and aortic incompetence. (1977) (3)
- Sarcoidosis: do our genes really matter? (2001) (3)
- Idiopathic interstitial pneumonias: a re-appraisal of idiopathic pulmonary fibrosis. (2001) (3)
- Presence of a partially acid‐labile alpha‐interferon in bronchoalveolar lavage fluid of patients with cytomegalovirus pneumonitis is associated with a poor prognosis (1988) (3)
- The alveolar macrophage in sarcoidosis. (1990) (2)
- Mimics of sarcoidosis. Extrinsic allergic alveolitis. (1991) (2)
- Fibroblastic foci: time to be counted? (2006) (2)
- The application of high-resolution CT to diagnosis in diffuse parenchymal lung disease. (2001) (2)
- Idiopathic pulmonary fibrosis: now less idiopathic? (2009) (2)
- In vitro pharmacoregulation of CC chemokine ligand 5 and its receptor CCR5 in diffuse lung diseases. (2003) (1)
- Focusing on diffuse (interstitial) lung disease: a rapidly evolving field (2002) (1)
- Does the lung work? 6. Pictures in the mind. (1983) (1)
- How T cells recognise antigen: implications for lung diseases. (1992) (1)
- Advances in our understanding of the pathogenesis of fibrotic lung disease. (1990) (1)
- Genetics of pulmonary fibrosis. (2003) (1)
- Management of idiopathic pulmonary fibrosis: prognostic indicators. (1997) (1)
- Elucidating the causes and examining the latest clinical findings in pulmonary fibrosis: recent progress and future objectives (2008) (1)
- Respiratory Medicine (1990) (0)
- Corticosteroids in sarcoidosis: friend or foe? (1994) (0)
- Blocking endothelin: breaking new ground (2007) (0)
- Rapid diagnosis of cytomegalovirus infection. (1985) (0)
- Management of fibrosing alveolitis. (1992) (0)
- Cytokines (1993) (0)
- The alveolar macrophage. (1985) (0)
- Introduction (1999) (0)
- Pathogenetic mechanisms in the lung in systemic disease. (1988) (0)
- Diffuse Lung Disease: Combined Clinical and Laboratory Studies (1994) (0)
- High resolution computed tomography as a predictor of lung histology in systemic sclerosis (1992) (0)
- Postgraduate Course ERS Copenhagen 2005 - Therapeutic options for interstitial lung diseases in 2005 (2006) (0)
- Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia (2016) (0)
This paper list is powered by the following services:
